Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

At the interface between the innate and adaptive immune system, dendritic cells (DCs) play
key roles in tumour immunity and hold a hitherto unrealized potential for cancer …

Dendritic cells (DC) are professional antigen presenting cells, uniquely able to induce naïve
T cell activation and effector differentiation. They are, likewise, involved in the induction and …

Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

The complexity of the tumor immunoenvironment is underscored by the emergence and
discovery of different subsets of immune effectors and regulatory cells. Tumor-induced …

The failure of the immune system to provide protection against tumour cells is an important
immunological problem. It is now evident that inadequate function of the host immune …

Infusion of either embryonic or mesenchymal stem cells prolongs the survival of organ
transplants derived from stem cell donors and prevents graft-versus-host-disease (GVHD) …

Insulin-like growth factor 2 (IGF2) is upregulated in both childhood and adult malignancies.
Its overexpression is associated with resistance to chemotherapy and worse prognosis …

T cell therapies require the removal and culture of T cells ex vivo to expand several
thousand‐fold. However, these cells often lose the phenotype and cytotoxic functionality for …

Abnormal dendritic cell differentiation and accumulation of immature myeloid suppressor
cells (ImC) is one of the major mechanisms of tumor escape. We tested the possibility of …